Introduction: Decoding How Lactate Rewrites Tumor Suppression
Metabolic reprogramming is one of the defining hallmarks of cancer. The Warburg effect describes how tumor cells preferentially rely on aerobic glycolysis even in the presence of sufficient oxygen, leading to excessive lactate accumulation within the tumor microenvironment. Once considered merely a metabolic byproduct, lactate has emerged as an active regulator of cellular signaling and gene expression since the discovery of histone lysine lactylation in 2019.
Growing evidence has demonstrated that lactylation participates in diverse biological processes, from DNA damage repair to tumor progression. Yet one fundamental question has remained unanswered: How do cells sense intracellular lactate and convert this metabolic signal into protein lactylation?
At the same time, the tumor suppressor p53, whose activity is tightly regulated by post-translational modifications, represents one of the most critical barriers against malignant transformation. Whether lactate directly influences p53 function through a dedicated molecular mechanism has long remained unknown.
Research Discovery: AARS1 Identified as Both a Lactate Sensor and Lactyltransferase
A groundbreaking study published in Cell, titled "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis," led by Prof. Fangfang Zhou's team at Soochow University, uncovered a previously unknown mechanism connecting lactate metabolism to tumor development.
The researchers first demonstrated that tumor-derived lactate acts as a natural inhibitor of p53 by promoting its lactylation, establishing a direct molecular link between metabolic dysregulation and impaired tumor suppression.
Through genome-wide CRISPR screening, the team identified Alanyl-tRNA Synthetase 1 (AARS1) as the strongest regulator of lysine lactylation. Traditionally known for its role in protein translation, AARS1 was found to possess an unexpected second function—it directly binds lactate and functions as both an intracellular lactate sensor and a lactyltransferase.
Mechanistic studies further revealed that AARS1 activates lactate through an ATP-dependent reaction, generating a reactive lactyl-AMP intermediate that transfers lactyl groups onto lysine residues of substrate proteins. This previously unrecognized enzymatic activity establishes AARS1 as a central molecular bridge connecting metabolic signals with post-translational modification.
Most importantly, AARS1 was shown to catalyze lactylation of p53 at K120 and K139, two residues located within its DNA-binding domain. These modifications weakened DNA binding, disrupted liquid-liquid phase separation (LLPS), reduced transcriptional activity, and ultimately promoted tumorigenesis.
Core Breakthrough: PTM BIO’s Lactylation Proteomics Captures the Critical Regulatory Network
Uncovering this previously hidden regulatory mechanism required comprehensive profiling of lactylated proteins across complex biological samples.
To systematically characterize AARS1-regulated lactylation events, the research team employed PTM BIO’s Lactylation Proteomics platform, enabling global analysis of lysine lactylation following AARS1 depletion and overexpression.
The proteomic data revealed that silencing AARS1 caused a dramatic reduction in the cellular lactylation landscape. Approximately 80% of lactylated peptides and proteins showed significantly decreased abundance, while nearly 10% declined by more than tenfold, providing compelling evidence that AARS1 functions as a master regulator of cellular lactylation.
Mass spectrometry further identified p53 lactylation at K120 and K139, while PTM BIO’s site-specific p53 lactylation antibodies independently confirmed modification at these endogenous residues. Together with biochemical validation, these findings established AARS1 as the direct enzyme responsible for catalyzing p53 lactylation.
Rather than relying solely on candidate-based approaches, the integration of global lactylation proteomics with targeted validation enabled researchers to move from broad modification screening to precise mechanistic understanding.
PTM BIO: Empowering Mechanistic Discovery Through Integrated PTMomics Solutions
In this landmark Cell study, PTM BIO provided critical research tools and technical support that helped translate complex modification signals into biological insight.
Comprehensive Lactylation Detection
Lactylated proteins often exist at relatively low abundance, making sensitive enrichment and detection essential. PTM BIO’s optimized lactylation enrichment workflow supported comprehensive profiling of modification events across biological samples, enabling systematic identification of AARS1-regulated substrates.
Orthogonal Validation for High-Confidence Discovery
Beyond discovery proteomics, PTM BIO supplied pan-acetylation/lactylation antibodies, p53 site-specific lactylation antibodies, and lactylation enrichment resin, allowing researchers to validate key findings through multiple complementary experimental approaches.
Building a Complete PTMomics Research Workflow
From global modification profiling to site-specific validation, PTM BIO’s integrated PTMomics solutions helped establish a robust experimental workflow that strengthened mechanistic interpretation and accelerated biological discovery.
Scientific Impact: Connecting Cancer Metabolism with Precision Therapeutic Opportunities
This study fundamentally reshapes our understanding of how metabolic signals regulate tumor suppression.
By identifying AARS1 as both a lactate sensor and lactyltransferase, the research reveals how elevated lactate directly rewires p53 function through post-translational modification. The work also provides a mechanistic explanation for cancer-associated mutations at p53 K120 and K139, which phenocopy the functional consequences of lactylation.
Importantly, the study extends beyond mechanism into translational relevance. Analysis of patient-derived tumor samples demonstrated positive correlations among AARS1 expression, global lactylation levels, and p53 lactylation, highlighting the clinical significance of this regulatory pathway.
The researchers further showed that β-alanine, a widely used nutritional supplement, competitively inhibits AARS1-mediated p53 lactylation, restores p53 activity, and enhances chemotherapy efficacy in experimental models. These findings open promising new avenues for targeting lactate-dependent signaling in cancer therapy.
PTM BIO: Advancing the Future of PTMomics Research
As a leader in proteomics-driven life science research, PTM BIO is committed to helping researchers uncover hidden layers of biological regulation through advanced mass spectrometry technologies and high-performance PTMomics solutions.
Our integrated platform—including lactylation proteomics, phosphorylation proteomics, acetylation proteomics, novel acylation profiling, high-quality modification antibodies, and targeted validation technologies—supports researchers worldwide in transforming complex molecular data into meaningful biological discoveries.
From comprehensive modification mapping to mechanistic validation, PTM BIO continues to empower next-generation discoveries across cancer biology, metabolism, immunology, developmental biology, and beyond.
